Abstract
Objective: To prospectively study real-world efficacy and safety of secukinumab in psoriatic arthritis (PsA) patients from the Israeli registry of inflammatory diseases. Methods: PsA patients fulfilling the CASPAR criteria were included in the analysis from 2010 to 2019. The primary endpoint was secukinumab drug retention compared to other TNF-α inhibitors (TNFi). Bivariate and multivariate analyses were made by Cox regression analysis. Drug retention according to treatment line was examined with Kaplan-Meier curves. Results: Included were 404 PsA patients who had 709 treatment courses during the study period. Ninety patients had been treated with secukinumab (22%). The secukinumab-treated patients were significantly older and their disease duration was longer. Secukinumab was less likely to be the first line of treatment compared to TNFi. Secukinumab had a drug retention comparable to TNFi, and a better drug retention than TNFi among biologic-experienced patients. Neither methotrexate combination nor body mass index affected the inefficacy event rate. Secukinumab had a similar rate of adverse events as TNFi. Conclusion: This multicentre real-world study demonstrated that secukinumab had a drug retention comparable to TNFi. Secukinumab had a better drug retention than TNFi among biologic-experienced patients. IL-17 inhibition is an effective mechanism of action to treat PsA in real life.
Original language | English |
---|---|
Pages (from-to) | 15-23 |
Number of pages | 9 |
Journal | Clinical and Experimental Rheumatology |
Volume | 40 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2022 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© Copyright Clinical and Experimental Rheumatology 2022.
Keywords
- Drug retention
- Psoriatic arthritis
- Real-world
- Secukinumab
- TNFα inhibitors
- Arthritis, Psoriatic/diagnosis
- Humans
- Treatment Outcome
- Tumor Necrosis Factor Inhibitors
- Antibodies, Monoclonal, Humanized
- Antirheumatic Agents/adverse effects
- Pharmaceutical Preparations
- Tumor Necrosis Factor-alpha/therapeutic use
ASJC Scopus subject areas
- Immunology and Allergy
- Rheumatology
- Immunology